Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 21;11(4):e9860.
doi: 10.5812/ijem.9860. eCollection 2013 Oct.

Female pattern hair loss

Ingrid Herskovitz  1 , Antonella Tosti  1
Affiliations
Review

Female pattern hair loss

Ingrid Herskovitz et al. Int J Endocrinol Metab. .

Abstract

Context: Female pattern hair loss (FPHL) also known as female androgenetic alopecia is a common condition afflicting millions of women that can be cosmetically disrupting. Prompt diagnosis and treatment are essential for obtaining optimal outcome. This review addresses the clinical presentation of female pattern hair loss, its differential diagnosis and treatment modalities.

Evidence acquisition: A) Diffuse thinning of the crown region with preservation of the frontal hairline (Ludwig's type) B) The "Christmas tree pattern" where the thinning is wider in the frontal scalp giving the alopecic area a triangular shaped figure resembling a christmas tree. C) Thinning associated with bitemporal recession (Hamilton type). Generally, FPHL is not associated with elevated androgens. Less commonly females with FPHL may have other skin or general signs of hyperandrogenism such as hirsutism, acne, irregular menses, infertility, galactorrhea and insulin resistance. The most common endocrinological abnormality associated with FPHL is polycystic ovarian syndrome (PCOS).

Results: The most important diseases to consider in the differential diagnosis of FPHL include Chronic Telogen Effluvium (CTE), Permanent Alopecia after Chemotherapy (PAC), Alopecia Areata Incognito (AAI) and Frontal Fibrosing Alopecia (FFA). This review describes criteria for distinguishing these conditions from FPHL.

Conclusions: The only approved treatment for FPHL, which is 2% topical Minoxidil, should be applied at the dosage of 1ml twice day for a minimum period of 12 months. This review will discuss off-label alternative modalities of treatment including 5-alfa reductase inhibitors, antiandrogens, estrogens, prostaglandin analogs, lasers, light treatments and hair transplantation.

Keywords: Alopecia, Therapy; Alopecia, physiopathology; Androgen antagonist, Therapeutic Use; Female; Minoxidil; Polycystic Ovary Syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. FPHL: Ludwig Type
Severity: Ludwig 2/ Sinclair 4
Figure 2.
Figure 2.. CTE: Note Typical Temporal Recession.
The hair density is otherwise normal
Figure 3.
Figure 3.. FFA: Scarring alopecia with recession of frontal hairline and alopecia of the eyebrows.
Note peripilar papules
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5–15. doi: 10.1111/j.1365-2133.2010.10011.x. - DOI - PubMed
    1. Leavitt M. Understanding and management of female pattern alopecia. Facial Plast Surg. 2008;24(4):414–27. doi: 10.1055/s-0028-1102905. - DOI - PubMed
    1. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004;123(3):455–7. doi: 10.1111/j.0022-202X.2004.23237.x. - DOI - PubMed
    1. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297–304. - PubMed
    1. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001;27(1):53–4. - PubMed